Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 4/20 | 0.78 |
| ▸ | POLA1 | P09884 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.70 |
| ▸ | ST6GAL1 | P15907 | 2/20 | 0.60 |
| ▸ | VDR | P11473 | 3/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.57 |
| ▸ | OSBP | P22059 | 1/20 | 0.56 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.56 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.56 |
| ▸ | FGF1 | P05230 | 1/20 | 0.55 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26693323 | 1.00 | CDC25A (0.78) | CDC25APOLA1CYP2D6CYP2C19INPP5D | |
| SCHEMBL13083162 | 1.00 | CDC25A (0.78) | CDC25APOLA1CYP2D6CYP2C19INPP5D | |
| SCHEMBL26912861 | 1.00 | CDC25A (0.78) | CDC25APOLA1CYP2D6CYP2C19INPP5D | |
| SCHEMBL19184920 | 1.00 | CDC25A (0.78) | CDC25APOLA1CYP2D6CYP2C19INPP5D | |
| SCHEMBL11994855 | 1.00 | CDC25A (0.78) | CDC25APOLA1CYP2D6CYP2C19INPP5D | |
| SCHEMBL4735227 | 1.00 | CDC25A (0.78) | CDC25APOLA1CYP2D6CYP2C19INPP5D | |
| SCHEMBL10017499 | 0.93 | CDC25A (0.68) | CDC25APOLA1CYP2D6CYP2C19INPP5D | |
| SCHEMBL12086538 | 0.93 | CDC25A (0.74) | CDC25APOLA1CYP2D6CYP2C19INPP5D | |
| SCHEMBL15113084 | 0.93 | CDC25A (0.74) | CDC25APOLA1CYP2D6CYP2C19INPP5D | |
| SCHEMBL4739096 | 0.93 | CDC25A (0.74) | CDC25APOLA1CYP2D6CYP2C19INPP5D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391817-A1 | 5ALPHA-HYDROXY-6BETA-[2-(1-H-IMIDAZOL-4-YL)-ETHYLAMINO]-CHOLESTAN-3BETA-OL ANALOGUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME FOR USE IN THE TREATMENT OF CANCER | DENDROGENIX (BE) | 2023-12-07 | — | — | US | disclosed |
| US-11339328-B2 | Liquid crystal composition containing polymerizable compound and display device thereof | JIANGSU HECHENG DISPLAY TECHNOLOGY CO., LTD. (CN) | 2022-05-24 | — | — | US | disclosed |
| US-20210284910-A1 | LIQUID CRYSTAL COMPOSITION CONTAINING POLYMERIZABLE COMPOUND AND DISPLAY DEVICE THEREOF | JIANGSU HECHENG DISPLAY TECHNOLOGY CO., LTD. (CN) | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391817-A1 | 5ALPHA-HYDROXY-6BETA-[2-(1-H-IMIDAZOL-4-YL)-ETHYLAMINO]-CHOLESTAN-3BETA-OL ANALOGUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME FOR USE IN THE TREATMENT OF CANCER | CYP46A1, CYP27A1, DHCR7 | CDC25A 881/4885POLA1 2099/4885CYP2D6 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.